Stockscreener 앱 받기
5.2681
11.31%
0.4881
전일 마감가:
$4.78
열려 있는:
$4.87
하루 거래량:
29,098
Relative Volume:
0.79
시가총액:
$155.82M
수익:
$15.33M
순이익/손실:
$-40.19M
주가수익비율:
-3.0066
EPS:
-1.7522
순현금흐름:
-
1주 성능:
+5.98%
1개월 성능:
+38.19%
6개월 성능:
+0.20%
1년 성능:
-39.88%
1일 변동 폭
$4.87
$5.3204
1주일 범위
$4.72
$5.21
52주 변동 폭
$3.50
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
TLSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.3204 | 155.82M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
112.92 | 196.55B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.24 | 141.03B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
365.62 | 139.65B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
81.55 | 104.60B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.35 | 43.28B | 6.60B | 4.16B | 490.10M | 6.93 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus Life Sciences announces publication of pre-clinical data - Yahoo Finance
TriSalus's TriNav System Shows Breakthrough 227% Increase in Liver Cancer Drug Delivery Efficacy - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
TLSITriSalus Life Sciences, Inc. Latest Stock News & Market Updates - StockTitan
TriSalus Announces Leadership Changes and New Incentive Program - TipRanks
TriSalus Life Sciences names new finance chief - MSN
TriSalus Has Several Leadership Changes - MPO-mag
TriSalus Life Sciences reshuffles executive team - Investing.com
TriSalus Life Sciences Taps James Young as CFO - MarketWatch
TriSalus Life Sciences Strengthens Executive Team with Strategic Leadership Appointments for 2025 - StockTitan
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 22.8% in December - MarketBeat
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of TriSalus Life Sciences (TLSI) with Overweight Recommendation - MSN
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Trisalus life sciences officer sells $1,394 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in Stock - MarketBeat
Frankenius equity AB acquires shares in Trisalus Life Sciences for $249,998 - Investing.com
Trisalus life sciences officer sells $1,394 in stock - Investing.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Cantor Fitzgerald - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus Price Target from Analysts - Defense World
Great-West Lifeco Inc. (TSE:GWO) Receives C$47.63 Consensus Price Target from Analysts - Defense World
Analysts Set Forward Air Co. (NASDAQ:FWRD) PT at $39.25 - Defense World
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $9.33 - Defense World
Safe Bulkers (NYSE:SB) versus Euronav (NYSE:CMBT) Financial Survey - Defense World
Stock Traders Buy High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA) - Defense World
TriSalus Life Sciences Forms Strategic Partnership With Geo-Med - MPO-mag
TriSalus Expands PEDD Portfolio - MPO-mag
Cantor Fitzgerald Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI) - MarketBeat
Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $12.08 - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Increase in Short Interest - MarketBeat
TriSalus Life Sciences director sells $110,700 in stock By Investing.com - Investing.com Canada
TriSalus Life Sciences director sells $110,700 in stock - Investing.com India
Director Arjun Desai Sells 30,000 Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus.com
Liver Cancer Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight - EIN News
Northland Capmk Brokers Increase Earnings Estimates for TLSI - MarketBeat
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com
Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK
Friday's Insider Moves: Top Executives Make Notable Stock Transactions - Investing.com India
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia
Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World
Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada
TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat
TriSalus Life Sciences Inc (TLSI) Quarterly 10-Q Report - Quartzy
MedTech Acquisition (OTCMKTS:MTACU) Files 8-K Report with SEC Announcement - Defense World
TriSalus Life Sciences Reports Strong Q3 Growth - TipRanks
TriSalus Reports Q3 2024 Financial Results and Provides Business Update - BioSpace
TriSalus Life Sciences Revenue Soars 42% in Q3, Expands into $375M Market | TLSI Stock News - StockTitan
TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Previe - GuruFocus.com
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Trisalus Life Sciences Inc 주식 (TLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Frankenius Equity AB | 10% Owner |
Dec 17 '24 |
Buy |
3.97 |
62,972 |
249,999 |
6,230,748 |
| Desai Arjun JJ | Director |
Dec 10 '24 |
Sale |
3.69 |
30,000 |
110,700 |
247,127 |
0.73%
2.52%
자본화:
|
볼륨(24시간):